Evaluating Suspected Cardiac Amyloidosis

por Motwani, Manish, Arumugam, Parthiban, Rocci, Alberto, Venetucci, Luigi
Publicado 2019

RWD-derived response in multiple myeloma

por Xu, Tao, Roose, James, Williamson, Mellissa, Sawas, Ahmed, Hong, Wan-Jen, Jin, Huan, Maignan, Kathleen, Rocci, Alberto, Yousefi, Kasra, Kumar, Shaji, Tyanova, Stefka
Publicado 2023

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

por Bonanno, Giuseppina, Mariotti, Andrea, Procoli, Annabella, Folgiero, Valentina, Natale, Daniela, De Rosa, Luca, Majolino, Ignazio, Novarese, Linda, Rocci, Alberto, Gambella, Manuela, Ciciarello, Marilena, Scambia, Giovanni, Palumbo, Antonio, Locatelli, Franco, De Cristofaro, Raimondo, Rutella, Sergio
Publicado 2012

Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

por Oliva, Stefania, Gambella, Manuela, Gilestro, Milena, Muccio, Vittorio Emanuele, Gay, Francesca, Drandi, Daniela, Ferrero, Simone, Passera, Roberto, Pautasso, Chiara, Bernardini, Annalisa, Genuardi, Mariella, Patriarca, Francesca, Saraci, Elona, Petrucci, Maria Teresa, Pescosta, Norbert, Liberati, Anna Marina, Caravita, Tommaso, Conticello, Concetta, Rocci, Alberto, Musto, Pellegrino, Boccadoro, Mario, Palumbo, Antonio, Omedè, Paola
Publicado 2016

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

por Pichiorri, Flavia, Palmieri, Dario, De Luca, Luciana, Consiglio, Jessica, You, Jia, Rocci, Alberto, Talabere, Tiffany, Piovan, Claudia, Lagana, Alessandro, Cascione, Luciano, Guan, Jingwen, Gasparini, Pierluigi, Balatti, Veronica, Nuovo, Gerard, Coppola, Vincenzo, Hofmeister, Craig C., Marcucci, Guido, Byrd, John C., Volinia, Stefano, Shapiro, Charles L., Freitas, Michael A., Croce, Carlo M.
Publicado 2013

Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

por Pichiorri, Flavia, Palmieri, Dario, De Luca, Luciana, Consiglio, Jessica, You, Jia, Rocci, Alberto, Talabere, Tiffany, Piovan, Claudia, Lagana, Alessandro, Cascione, Luciano, Guan, Jingwen, Gasparini, Pierluigi, Balatti, Veronica, Nuovo, Gerard, Coppola, Vincenzo, Hofmeister, Craig C., Marcucci, Guido, Byrd, John C., Volinia, Stefano, Shapiro, Charles L., Freitas, Michael A., Croce, Carlo M.
Publicado 2017

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

por Dimopoulos, Meletios A., Jakubowiak, Andrzej J., McCarthy, Philip L., Orlowski, Robert Z., Attal, Michel, Bladé, Joan, Goldschmidt, Hartmut, Weisel, Katja C., Ramasamy, Karthik, Zweegman, Sonja, Spencer, Andrew, Huang, Jeffrey S. Y., Lu, Jin, Sunami, Kazutaka, Iida, Shinsuke, Chng, Wee-Joo, Holstein, Sarah A., Rocci, Alberto, Skacel, Tomas, Labotka, Richard, Palumbo, Antonio, Anderson, Kenneth C.
Publicado 2020

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

por Tornatore, Laura, Sandomenico, Annamaria, Raimondo, Domenico, Low, Caroline, Rocci, Alberto, Tralau-Stewart, Cathy, Capece, Daria, D’Andrea, Daniel, Bua, Marco, Boyle, Eileen, van Duin, Mark, Zoppoli, Pietro, Jaxa-Chamiec, Albert, Thotakura, Anil K., Dyson, Julian, Walker, Brian A., Leonardi, Antonio, Chambery, Angela, Driessen, Christoph, Sonneveld, Pieter, Morgan, Gareth, Palumbo, Antonio, Tramontano, Anna, Rahemtulla, Amin, Ruvo, Menotti, Franzoso, Guido
Publicado 2014

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

por Tornatore, Laura, Sandomenico, Annamaria, Raimondo, Domenico, Low, Caroline, Rocci, Alberto, Tralau-Stewart, Cathy, Capece, Daria, D’Andrea, Daniel, Bua, Marco, Boyle, Eileen, van Duin, Mark, Zoppoli, Pietro, Jaxa-Chamiec, Albert, Thotakura, Anil K., Dyson, Julian, Walker, Brian A., Leonardi, Antonio, Chambery, Angela, Driessen, Christoph, Sonneveld, Pieter, Morgan, Gareth, Palumbo, Antonio, Tramontano, Anna, Rahemtulla, Amin, Ruvo, Menotti, Franzoso, Guido
Publicado 2014

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim...

por Jackson, Graham H., Pawlyn, Charlotte, Cairns, David A., de Tute, Ruth M., Hockaday, Anna, Collett, Corinne, Jones, John R., Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D., Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A., Jenner, Matthew W., Cook, Gordon, Russell, Nigel H., Drayson, Mark T., Gregory, Walter M., Kaiser, Martin F., Owen, Roger G., Davies, Faith E., Morgan, Gareth J.
Publicado 2021